vs
徕博科（LH）与PAR PACIFIC HOLDINGS, INC.（PARR）财务数据对比。点击上方公司名可切换其他公司
徕博科的季度营收约是PAR PACIFIC HOLDINGS, INC.的1.9倍（$3.5B vs $1.8B），徕博科净利率更高（4.7% vs 4.3%，领先0.4%），徕博科同比增速更快（5.6% vs -1.0%），徕博科自由现金流更多（$490.3M vs $66.3M），过去两年徕博科的营收复合增速更高（5.2% vs -4.3%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
Par Pacific Holdings是总部位于美国休斯顿的油气勘探生产企业，曾在破产重组后以Par Petroleum Corporation为名运营，2015年10月20日正式更名为现名，2017年入选《财富》美国1000强企业。
LH vs PARR — 直观对比
营收规模更大
LH
是对方的1.9倍
$1.8B
营收增速更快
LH
高出6.6%
-1.0%
净利率更高
LH
高出0.4%
4.3%
自由现金流更多
LH
多$424.0M
$66.3M
两年增速更快
LH
近两年复合增速
-4.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $1.8B |
| 净利润 | $164.7M | $77.7M |
| 毛利率 | 28.2% | — |
| 营业利润率 | 7.6% | 5.5% |
| 净利率 | 4.7% | 4.3% |
| 营收同比 | 5.6% | -1.0% |
| 净利润同比 | 14.9% | 239.5% |
| 每股收益（稀释后） | $1.98 | $1.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHPARR
| Q4 25 | $3.5B | $1.8B | ||
| Q3 25 | $3.6B | $2.0B | ||
| Q2 25 | $3.5B | $1.9B | ||
| Q1 25 | $3.3B | $1.7B | ||
| Q4 24 | $3.3B | $1.8B | ||
| Q3 24 | $3.3B | $2.1B | ||
| Q2 24 | $3.2B | $2.0B | ||
| Q1 24 | $3.2B | $2.0B |
净利润LHPARR
| Q4 25 | $164.7M | $77.7M | ||
| Q3 25 | $261.1M | $262.6M | ||
| Q2 25 | $237.9M | $59.5M | ||
| Q1 25 | $212.8M | $-30.4M | ||
| Q4 24 | $143.4M | $-55.7M | ||
| Q3 24 | $169.3M | $7.5M | ||
| Q2 24 | $205.3M | $18.6M | ||
| Q1 24 | $228.0M | $-3.8M |
毛利率LHPARR
| Q4 25 | 28.2% | — | ||
| Q3 25 | 28.8% | — | ||
| Q2 25 | 29.7% | — | ||
| Q1 25 | 28.3% | — | ||
| Q4 24 | 26.9% | — | ||
| Q3 24 | 27.6% | — | ||
| Q2 24 | 28.8% | — | ||
| Q1 24 | 28.2% | — |
营业利润率LHPARR
| Q4 25 | 7.6% | 5.5% | ||
| Q3 25 | 11.1% | 17.8% | ||
| Q2 25 | 11.2% | 5.1% | ||
| Q1 25 | 9.7% | -0.9% | ||
| Q4 24 | 6.5% | -2.6% | ||
| Q3 24 | 7.7% | 1.7% | ||
| Q2 24 | 9.2% | 2.4% | ||
| Q1 24 | 10.1% | 0.5% |
净利率LHPARR
| Q4 25 | 4.7% | 4.3% | ||
| Q3 25 | 7.3% | 13.0% | ||
| Q2 25 | 6.7% | 3.1% | ||
| Q1 25 | 6.4% | -1.7% | ||
| Q4 24 | 4.3% | -3.0% | ||
| Q3 24 | 5.2% | 0.3% | ||
| Q2 24 | 6.4% | 0.9% | ||
| Q1 24 | 7.2% | -0.2% |
每股收益（稀释后）LHPARR
| Q4 25 | $1.98 | $1.40 | ||
| Q3 25 | $3.12 | $5.16 | ||
| Q2 25 | $2.84 | $1.17 | ||
| Q1 25 | $2.52 | $-0.57 | ||
| Q4 24 | $1.72 | $-0.98 | ||
| Q3 24 | $2.00 | $0.13 | ||
| Q2 24 | $2.43 | $0.32 | ||
| Q1 24 | $2.69 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $164.1M |
| 总债务越低越好 | — | $802.9M |
| 股东权益账面价值 | $8.6B | $1.5B |
| 总资产 | $18.4B | $3.8B |
| 负债/权益比越低杠杆越低 | — | 0.53× |
8季度趋势，按日历期对齐
现金及短期投资LHPARR
| Q4 25 | $532.3M | $164.1M | ||
| Q3 25 | $598.1M | $159.1M | ||
| Q2 25 | $647.3M | $169.2M | ||
| Q1 25 | $369.4M | $133.7M | ||
| Q4 24 | $1.5B | $191.9M | ||
| Q3 24 | $1.5B | $183.0M | ||
| Q2 24 | $265.1M | $179.7M | ||
| Q1 24 | $99.3M | $228.3M |
总债务LHPARR
| Q4 25 | — | $802.9M | ||
| Q3 25 | — | $967.1M | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $639.5M |
股东权益LHPARR
| Q4 25 | $8.6B | $1.5B | ||
| Q3 25 | $8.7B | $1.4B | ||
| Q2 25 | $8.5B | $1.1B | ||
| Q1 25 | $8.3B | $1.1B | ||
| Q4 24 | $8.1B | $1.2B | ||
| Q3 24 | $8.2B | $1.3B | ||
| Q2 24 | $8.0B | $1.3B | ||
| Q1 24 | $8.0B | $1.3B |
总资产LHPARR
| Q4 25 | $18.4B | $3.8B | ||
| Q3 25 | $18.3B | $4.1B | ||
| Q2 25 | $18.1B | $3.9B | ||
| Q1 25 | $17.6B | $3.8B | ||
| Q4 24 | $18.4B | $3.8B | ||
| Q3 24 | $18.6B | $3.9B | ||
| Q2 24 | $16.7B | $3.9B | ||
| Q1 24 | $16.5B | $3.8B |
负债/权益比LHPARR
| Q4 25 | — | 0.53× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 1.04× | ||
| Q4 24 | — | 0.93× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | 0.84× | ||
| Q1 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $93.8M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $66.3M |
| 自由现金流率自由现金流/营收 | 13.9% | 3.7% |
| 资本支出强度资本支出/营收 | 3.5% | 1.5% |
| 现金转化率经营现金流/净利润 | 3.73× | 1.21× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $296.5M |
8季度趋势，按日历期对齐
经营现金流LHPARR
| Q4 25 | $614.2M | $93.8M | ||
| Q3 25 | $387.2M | $219.4M | ||
| Q2 25 | $620.6M | $133.6M | ||
| Q1 25 | $18.5M | $-1.4M | ||
| Q4 24 | $777.2M | $-15.5M | ||
| Q3 24 | $277.3M | $78.5M | ||
| Q2 24 | $561.1M | $-4.7M | ||
| Q1 24 | $-29.8M | $25.4M |
自由现金流LHPARR
| Q4 25 | $490.3M | $66.3M | ||
| Q3 25 | $280.5M | $187.1M | ||
| Q2 25 | $542.7M | $85.5M | ||
| Q1 25 | $-107.5M | $-42.3M | ||
| Q4 24 | $665.1M | $-63.1M | ||
| Q3 24 | $161.5M | $50.2M | ||
| Q2 24 | $432.9M | $-41.6M | ||
| Q1 24 | $-163.6M | $2.8M |
自由现金流率LHPARR
| Q4 25 | 13.9% | 3.7% | ||
| Q3 25 | 7.9% | 9.3% | ||
| Q2 25 | 15.4% | 4.5% | ||
| Q1 25 | -3.2% | -2.4% | ||
| Q4 24 | 20.0% | -3.4% | ||
| Q3 24 | 4.9% | 2.3% | ||
| Q2 24 | 13.4% | -2.1% | ||
| Q1 24 | -5.2% | 0.1% |
资本支出强度LHPARR
| Q4 25 | 3.5% | 1.5% | ||
| Q3 25 | 3.0% | 1.6% | ||
| Q2 25 | 2.2% | 2.5% | ||
| Q1 25 | 3.8% | 2.3% | ||
| Q4 24 | 3.4% | 2.6% | ||
| Q3 24 | 3.5% | 1.3% | ||
| Q2 24 | 4.0% | 1.8% | ||
| Q1 24 | 4.2% | 1.1% |
现金转化率LHPARR
| Q4 25 | 3.73× | 1.21× | ||
| Q3 25 | 1.48× | 0.84× | ||
| Q2 25 | 2.61× | 2.25× | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | 5.42× | — | ||
| Q3 24 | 1.64× | 10.48× | ||
| Q2 24 | 2.73× | -0.25× | ||
| Q1 24 | -0.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
PARR
| Distillates | $750.6M | 41% |
| Gasoline | $603.9M | 33% |
| Other Refined Products | $348.8M | 19% |
| Logistics | $73.7M | 4% |
| Other Revenues | $44.8M | 2% |
